Drug Type Small molecule drug |
Synonyms Alogliptin/Actos, Alogliptin/Pioglitazone, Incresync + [11] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (25 Jan 2013), |
Regulation- |
Molecular FormulaC44H48ClN7O7S |
InChIKeyBVRQKMNFVHMFOV-FTBZCSGFSA-N |
CAS Registry1799503-95-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 25 Jan 2013 |
Phase 1 | - | 72 | (Regimen A) | fwudipfmwg(eqzatmfjuy): Least Square Mean (LSM) difference = 1.0706 (90% CI, 1.0230 - 1.1204), P-Value = 0.014; LSM diiference = 0.9594 (90% CI, 0.8837 - 1.0415), P-Value = 0.405 View more | - | 08 Aug 2019 | |
(Regimen B) | |||||||
Phase 1/2 | 82 | Placebo (Placebo - Heroin) | bdftjhnfnd(tdxioymujc) = skzwmstfib dgpsyogciz (umnelnfwbb, lgzssdullx - dvwovkmjam) View more | - | 13 Jul 2017 | ||
(Pio High Dose - Heroin) | bdftjhnfnd(tdxioymujc) = gngmrsdqrs dgpsyogciz (umnelnfwbb, wfhigzjyry - xhkwmobyde) View more |